
EquitySector - HealthcareVery High Risk
Direct
NAV (11-Nov-25)
Returns (Since Inception)
Fund Size
₹1,125 Cr
Expense Ratio
1.30%
ISIN
INF789F01TO9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
01 Jan 2013
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+2.76%
+1.22% (Cat Avg.)
3 Years
+25.01%
+22.41% (Cat Avg.)
5 Years
+18.94%
+18.83% (Cat Avg.)
10 Years
+13.18%
+13.53% (Cat Avg.)
Since Inception
+16.14%
— (Cat Avg.)
| Equity | ₹1,103.73 Cr | 98.12% |
| Others | ₹21.15 Cr | 1.88% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹109.9 Cr | 9.77% |
| Ajanta Pharma Ltd | Equity | ₹70.26 Cr | 6.25% |
| Lupin Ltd | Equity | ₹62.75 Cr | 5.58% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹46.33 Cr | 4.12% |
| Cipla Ltd | Equity | ₹42.04 Cr | 3.74% |
| Procter & Gamble Health Ltd | Equity | ₹41.32 Cr | 3.67% |
| Gland Pharma Ltd | Equity | ₹41.11 Cr | 3.65% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹40.71 Cr | 3.62% |
| Dr Reddy's Laboratories Ltd | Equity | ₹40.12 Cr | 3.57% |
| Alkem Laboratories Ltd | Equity | ₹39.65 Cr | 3.52% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹36.05 Cr | 3.20% |
| Divi's Laboratories Ltd | Equity | ₹33.69 Cr | 2.99% |
| Fortis Healthcare Ltd | Equity | ₹28.65 Cr | 2.55% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹28.52 Cr | 2.54% |
| Aurobindo Pharma Ltd | Equity | ₹28.47 Cr | 2.53% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹27.55 Cr | 2.45% |
| Cohance Lifesciences Ltd | Equity | ₹27.13 Cr | 2.41% |
| Caplin Point Laboratories Ltd | Equity | ₹26.6 Cr | 2.36% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹25.46 Cr | 2.26% |
| Sai Life Sciences Ltd | Equity | ₹21.08 Cr | 1.87% |
| Net Current Assets | Cash | ₹21.04 Cr | 1.87% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹20.68 Cr | 1.84% |
| Pfizer Ltd | Equity | ₹20.11 Cr | 1.79% |
| Ipca Laboratories Ltd | Equity | ₹19.98 Cr | 1.78% |
| Global Health Ltd | Equity | ₹19.41 Cr | 1.73% |
| Metropolis Healthcare Ltd | Equity | ₹19.06 Cr | 1.69% |
| Sequent Scientific Ltd | Equity | ₹18.7 Cr | 1.66% |
| Anthem Biosciences Ltd | Equity | ₹17.75 Cr | 1.58% |
| Windlas Biotech Ltd | Equity | ₹15.18 Cr | 1.35% |
| Marksans Pharma Ltd | Equity | ₹13.75 Cr | 1.22% |
| Acutaas Chemicals Ltd | Equity | ₹12.09 Cr | 1.08% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹11.86 Cr | 1.05% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹11.7 Cr | 1.04% |
| Syngene International Ltd | Equity | ₹11.7 Cr | 1.04% |
| Biocon Ltd | Equity | ₹11.16 Cr | 0.99% |
| Rainbow Childrens Medicare Ltd | Equity | ₹10.77 Cr | 0.96% |
| Torrent Pharmaceuticals Ltd | Equity | ₹10.68 Cr | 0.95% |
| Emcure Pharmaceuticals Ltd | Equity | ₹9.89 Cr | 0.88% |
| Jubilant Pharmova Ltd | Equity | ₹9.87 Cr | 0.88% |
| Alembic Pharmaceuticals Ltd | Equity | ₹9.81 Cr | 0.87% |
| Orchid Pharma Ltd | Equity | ₹7.26 Cr | 0.65% |
| Laxmi Dental Ltd | Equity | ₹4.8 Cr | 0.43% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.14 Cr | 0.01% |
| Clearing Corporation Of India Ltd. Std - Margin | Cash - Repurchase Agreement | ₹0.11 Cr | 0.01% |
Large Cap Stocks
32.66%
Mid Cap Stocks
23.46%
Small Cap Stocks
40.42%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹1,091.64 Cr | 97.05% |
| Basic Materials | ₹12.09 Cr | 1.08% |
Standard Deviation
This fund
15.79%
Cat. avg.
16.01%
Lower the better
Sharpe Ratio
This fund
1.09
Cat. avg.
0.93
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.67
Higher the better
Since May 2022
ISIN INF789F01TO9 | Expense Ratio 1.30% | Exit Load 1.00% | Fund Size ₹1,125 Cr | Age 12 years 10 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹3,42,779 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Your principal amount will be at Very High Risk


EquitySector - HealthcareVery High Risk
Direct
NAV (11-Nov-25)
Returns (Since Inception)
Fund Size
₹1,125 Cr
Expense Ratio
1.30%
ISIN
INF789F01TO9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
01 Jan 2013
Your principal amount will be at Very High Risk

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+2.76%
+1.22% (Cat Avg.)
3 Years
+25.01%
+22.41% (Cat Avg.)
5 Years
+18.94%
+18.83% (Cat Avg.)
10 Years
+13.18%
+13.53% (Cat Avg.)
Since Inception
+16.14%
— (Cat Avg.)
| Equity | ₹1,103.73 Cr | 98.12% |
| Others | ₹21.15 Cr | 1.88% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹109.9 Cr | 9.77% |
| Ajanta Pharma Ltd | Equity | ₹70.26 Cr | 6.25% |
| Lupin Ltd | Equity | ₹62.75 Cr | 5.58% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹46.33 Cr | 4.12% |
| Cipla Ltd | Equity | ₹42.04 Cr | 3.74% |
| Procter & Gamble Health Ltd | Equity | ₹41.32 Cr | 3.67% |
| Gland Pharma Ltd | Equity | ₹41.11 Cr | 3.65% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹40.71 Cr | 3.62% |
| Dr Reddy's Laboratories Ltd | Equity | ₹40.12 Cr | 3.57% |
| Alkem Laboratories Ltd | Equity | ₹39.65 Cr | 3.52% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹36.05 Cr | 3.20% |
| Divi's Laboratories Ltd | Equity | ₹33.69 Cr | 2.99% |
| Fortis Healthcare Ltd | Equity | ₹28.65 Cr | 2.55% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹28.52 Cr | 2.54% |
| Aurobindo Pharma Ltd | Equity | ₹28.47 Cr | 2.53% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹27.55 Cr | 2.45% |
| Cohance Lifesciences Ltd | Equity | ₹27.13 Cr | 2.41% |
| Caplin Point Laboratories Ltd | Equity | ₹26.6 Cr | 2.36% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹25.46 Cr | 2.26% |
| Sai Life Sciences Ltd | Equity | ₹21.08 Cr | 1.87% |
| Net Current Assets | Cash | ₹21.04 Cr | 1.87% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹20.68 Cr | 1.84% |
| Pfizer Ltd | Equity | ₹20.11 Cr | 1.79% |
| Ipca Laboratories Ltd | Equity | ₹19.98 Cr | 1.78% |
| Global Health Ltd | Equity | ₹19.41 Cr | 1.73% |
| Metropolis Healthcare Ltd | Equity | ₹19.06 Cr | 1.69% |
| Sequent Scientific Ltd | Equity | ₹18.7 Cr | 1.66% |
| Anthem Biosciences Ltd | Equity | ₹17.75 Cr | 1.58% |
| Windlas Biotech Ltd | Equity | ₹15.18 Cr | 1.35% |
| Marksans Pharma Ltd | Equity | ₹13.75 Cr | 1.22% |
| Acutaas Chemicals Ltd | Equity | ₹12.09 Cr | 1.08% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹11.86 Cr | 1.05% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹11.7 Cr | 1.04% |
| Syngene International Ltd | Equity | ₹11.7 Cr | 1.04% |
| Biocon Ltd | Equity | ₹11.16 Cr | 0.99% |
| Rainbow Childrens Medicare Ltd | Equity | ₹10.77 Cr | 0.96% |
| Torrent Pharmaceuticals Ltd | Equity | ₹10.68 Cr | 0.95% |
| Emcure Pharmaceuticals Ltd | Equity | ₹9.89 Cr | 0.88% |
| Jubilant Pharmova Ltd | Equity | ₹9.87 Cr | 0.88% |
| Alembic Pharmaceuticals Ltd | Equity | ₹9.81 Cr | 0.87% |
| Orchid Pharma Ltd | Equity | ₹7.26 Cr | 0.65% |
| Laxmi Dental Ltd | Equity | ₹4.8 Cr | 0.43% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.14 Cr | 0.01% |
| Clearing Corporation Of India Ltd. Std - Margin | Cash - Repurchase Agreement | ₹0.11 Cr | 0.01% |
Large Cap Stocks
32.66%
Mid Cap Stocks
23.46%
Small Cap Stocks
40.42%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹1,091.64 Cr | 97.05% |
| Basic Materials | ₹12.09 Cr | 1.08% |
Standard Deviation
This fund
15.79%
Cat. avg.
16.01%
Lower the better
Sharpe Ratio
This fund
1.09
Cat. avg.
0.93
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.67
Higher the better
Since May 2022
ISIN INF789F01TO9 | Expense Ratio 1.30% | Exit Load 1.00% | Fund Size ₹1,125 Cr | Age 12 years 10 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹3,42,779 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments